Skip to main content
    M

    Merck & Company Inc (MRK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $144.52
    -3.24 (-2.19%)

    Market Cap: $364.26B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Merck & Company Inc (MRK) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Merck & Company (MRK) trades at 46.3x trailing earnings and 5.3x sales. Its P/E of 46.3x is above its 5-year median of 14.6x. Its forward P/E is 16.3x. The median P/E across 9 similar companies is 19.9x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 184.0% higher over the next year. Its free cash flow yield is 4.1%.

    MultipleValue
    P/E (trailing)46.3x
    Forward P/E16.3x
    Price to sales5.3x
    Price to book7.9x
    EV/EBITDA33.1x
    Price to FCF24.2x
    EV/FCF27.2x
    PEG3.6
    FCF yield4.1%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 202.6% above 15.3x, its P/S is 15.2% above 4.6x and its P/B is 33.9% above 5.9x.

    MultipleCurrent5-year median10-year median
    P/E46.3x14.6x15.3x
    P/S5.3x4.4x4.6x
    P/B7.9x5.9x5.9x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 11.7x in 2025 to 72.7x in 2023. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$105.2611.7x4.0x5.0x
    2024$99.4813.0x3.9x5.5x
    2023$109.0272.7x4.6x7.4x
    2022$110.9514.8x4.7x6.1x
    2021$76.6412.2x4.0x5.1x
    2020$81.8013.8x5.0x8.2x
    2019$90.9517.5x6.0x9.0x
    2018$76.4117.6x4.8x7.5x
    2017$56.2714.1x3.8x4.4x
    2016$58.8715.6x4.1x4.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MRK

    What is MRK's forward P/E ratio?

    Merck & Company has a forward P/E ratio of 16.3x.

    Is MRK stock overvalued?

    GNG's valuation label for MRK is Overvalued. Its P/E of 46.3x compares with a median of 19.9x across 9 similar companies.

    What is MRK's price to sales ratio?

    Merck & Company has a price to sales ratio of 5.3x.

    What is Merck & Company's average P/E ratio over 5 years?

    Merck & Company's median P/E over the last 5 years is 14.6x, from 60 month-end values through Oct 2026.

    What is MRK's PEG ratio?

    Merck & Company has a PEG ratio of 3.6.